Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Haoning Lan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Diabetic Neuropathies. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Beijing Friendship Hospital Zhongzi Project.
Abstract (Originalsprache)
Aims
Effective, targeted drug therapies for diabetic polyneuropathy (DP) are currently lacking. This study was designed to pinpoint new drug targets to enhance treatment efficacy. Materials and Methods Using large‐scale clinical and genetic datasets, we scrutinised proteins potentially involved in the onset and progression of DP . We further probed their associations with clinical symptoms and risk factors, and explored potential pathogenic mechanisms via single‐cell sequencing.
Results
We identified six proteins linked to DP , with Tumour Necrosis Factor Receptor Superfamily Member 14 ( TNFRSF14 ) standing out as a particularly compelling target. Notably, TNFRSF14 levels correlated with clinical scale (as assessed by the Michigan Neuropathy Screening Instrument) and might mediate the impact of metabolic syndrome on DP . At the cellular level, single‐cell sequencing hinted that TNFRSF14 could drive DP progression by activating macrophages and compromising endothelial cell function.
Conclusions
TNFRSF14 emerges as a promising biomarker and therapeutic target for the early detection and specific treatment of DP, paving the way for improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Haoning Lan
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Friendship Hospital Zhongzi Project
Zitieren
APA
Lan, H., Xu, S., Li, H., Guo, R., Ma, D., Feng, Z., & Wang, Y. (2026). Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70239
Vancouver
Lan H, Xu S, Li H, Guo R, Ma D, Feng Z, et al. Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70239
BibTeX
@article{Lan2026,
author = {Lan, Haoning and Xu, Songchao and Li, Huili and Guo, Ruijuan and Ma, Danxu and Feng, Zhong and Wang, Yun},
title = {Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70239}
}
EUVIMED